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Introduction
Estimating prognosis is a fundamental component in the management of patients with advanced cancer for several reasons. Firstly, accurate estimation of prognosis can help inform whether anti-cancer treatment is likely to be beneficial. 1, 2 Secondly, it may relieve patient and carer anxiety associated with prognostic uncertainty. 3 Thirdly it can help with end of life care planning, including place of care.
However, in patients with advanced cancer the ceiling limit of the TNM classification system is often reached (i.e. M 1 ) and as such is of limited value. As such, in the clinic, prognosis is based on various factors including stage of disease, performance status, previous clinical experience and knowledge of cancer trajectories. However the subjective nature of these may result in estimates of prognosis which are inaccurate, potentially misleading and may result in anti-cancer therapies being given inappropriately. 2, [4] [5] [6] In an attempt to improve prognostic accuracy, in 2005the European Association of Palliative Care (EAPC) published recommendations on the use of prognostic markers in patients with advanced cancer. 7 These recommendations were informed by eight studies examining different prognostic tools, which had been published in the preceding decade (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) , and recommended a number of prognostic tools and their utilisation. These tools were: the Terminal Cancer Prognostic Score, the Palliative Performance Scale, the Palliative Prognostic Index and the Palliative Prognostic Score.
Since these recommendations were made, a plethora of prognostic tools devised for use in patients with advanced cancer have been developed, however to date they have not been presented together and comparison made. To this end, the aim of this systematic review, was M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 5 to examine and compare prognostic tools in patients with advanced cancer and make recommendations for their use.
Methods
The following databases were searched: Medline (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) , Embase Classic + and Embase (2003 -2015) . The search focussed on studies of prognostic tools in patients with advanced cancer regardless of the original primary tumour. The search terms are listed in Appendix 1. A hand search of key journals and relevant citations was carried out. The date of the last literature search was 30th April 2015.
Eligibility Criteria
Eligible studies met the following inclusion criteria: population with advanced cancer (defined as an incurable cancer); original studies; study population n >100 and age > 18 years; quantitative clinical and/or biomarkers were examined; a multivariate statistical model was described; the tool had been examined and validated in two or more independent data sets; published in English; published after 2003 (end date of original literature search); and full paper was available. 7 The primary outcome measurement examined was survival prediction (likelihood of death) based on the use of the prognostic tool in the specific patient population. Studies were excluded if: a univariate survival analysis was described only; the tool was designed for use in one specific population with one specific cancer type (e.g. only patients with specific stage of lung cancer) or qualitative indices were used exclusively to predict survival. The initial database search was undertaken and duplicates removed. Two authors (CS and KM) independently screened each study for eligibility based on the abstract and finally each full text article. From this, the necessary data for descriptive and quantitative analyses were extracted by CS and TS, independently. These included the descriptors of the patient population, length of survival and information regarding survival predictions. The analysis of each study was performed using standard quality assessment criteria which were then summarised for statistical analysis and comparison where possible. 8 Studies are presented according to the prognostic tool described. Where studies examined both populations with cancer and non-cancer, only those populations with cancer were included in the analysis.
Data extraction and analysis
Results
The literature search process is shown in Figure 1 . Following abstract review, 179 articles were reviewed in full and this resulted in 49 studies fulfilling the eligibility criteria.
From the 49 eligible studies, seven different prognostic tools were identified. A summary of these is detailed in Table 1 . The tools identified were the PaP (Palliative Prognostic Score -8 studies), D-PaP (Delirium-PaP -2 studies), BCI (B12/CRP Index -1 study), PiPS (Prognosis in Palliative Care Study-1 study), PPI (Palliative Prognostic Index -8 studies), PPS (Palliative Performance Scale -18 studies) and the GPS (Glasgow Prognostic Score -10 studies).
A detailed description of these seven prognostic tools is given in Appendices 2 and 3. These tools used a combination of clinical and/or biomarker parameters. The most common clinical parameters used were performance status, anorexia and dyspnoea. The most common biomarkers were C-reactive protein (CRP), white cell count, lymphocyte count and albumin.
The number of parameters used ranged from two (GPS, BCI) to 17 (PiPS B), and the mean number was seven. The largest single population studied for each of the prognostic tools is summarised in Table 2 . Details of all studies included in this review are summarised in Supplementary Table 1 .
To date, there have been eight studies (combined total n=2694) examining the PaP in patients with advanced cancer. Patient cohorts were unselected but included patients with a variety of cancer diagnoses including cancer of the head and neck, lung, skin, breast, gastrointestinal tract, genitourinary tract, prostate, gynaecological, neuroendocrine and haematological tissue.
The studies were from groups in Australia (1 study), Italy (2 studies), Brazil (1 study), Japan (1 study), Canada (2 studies) and the USA (1 study Eight studies (n= 5929) have examined the prognostic value of the PPI. 9, [13] [14] [15] [16] [17] [18] [19] [20] The patients included those with cancer of the head and neck, lung, breast, gastrointestinal tract, genitourinary tract, prostate, gynaecological and haematological tissue. The studies were based in Japan (3 studies), Italy (1 study), Taiwan (2 studies), USA (1 study) and Canada (1 study). Recently studies have examined a change in PPI scores, and this approach to researching the PPI appears more consistent, accurate and clinically useful.
Eighteen studies (n=21,082) have examined the PPS. The patients included those with diagnoses of cancer of the head and neck, lung, breast, gastrointestinal tract, genitourinary tract, prostate, gynaecological, neuroendocrine and haematological tissue. The studies were based in the USA (6 studies), Spain (1 study), Canada (8 studies), Italy (1 study), Singapore (1 study) and South Korea (1 study), thereby providing external validation of the tool. Due to the numerous subgroups within the tool, earlier reports had stated it was not highly discriminating in the intermediate scores. 7 Studies taking place after 2005 tackled this issue and focussed on the significance of a 10% decrement in PPS score or poorer PPS scores. A strong ordering effect across the different PPS categories was demonstrated, with highly accurate scores for a PPS of 40% or less. Patients with PPS categories greater than 50% had lower hazard ratios than patients with lower PPS scores.
Ten studies (n=5163) have examined the GPS. The patients included those with diagnoses of cancer of the head and neck, lung, skin, breast, gastrointestinal tract, genitourinary tract,
prostate, gynaecological, neuroendocrine and haematological tissue. Eight studies were from groups based in the UK, one study was from Japan and one study examined data from an international bio bank of patients, providing external validation of this tool.
A descriptive comparison of the individual clinical and biomarkers parameters included in the each of the prognostic tools is shown in Table 3 . The number of markers ranges from 2 (GPS) to 17 (PiPSB). The (PPS) is composed of 6 parameters (6 subjective), the Palliative Prognostic Score (PaP) composed of 6 parameters (4 subjective, 2 objective) the Palliative Prognostic Index (PPI) composed of 9 parameters (9 subjective), and the Glasgow Prognostic Score (GPS) composed of 2 parameters (2 objective).
To date, there have been limited studies on the direct comparison of the prognostic value of the above tools. One study compared the performance of the PaP to the D-PaP, PPS, and PPI and concluded that the PaP showed superior accuracy and reproducibility. 9 The PaP was also directly compared with the PPS and PPI tools in separate studies. 20, 21 Tarumi Finally, direct comparison has been carried out between the GPS and ECOG performance status, 22 and between the GPS and the PPI 23 and reported that the GPS had prognostic value independent of ECOG-PS 22 and PPI 22,23 .
Discussion
Since the European Association for Palliative Care recommendations for prognostic tools were published in 2005 there have been a number of prognostic tools developed, evolved, and validated. 7 The PPS has been studied in the greatest number of patients, externally validated and consistently predicts survival in patients with advanced cancer. Other prognostic tools of note, that have been validated and consistently predict survival are the PaP, the PPI, and the GPS. In addition, the latter (based on the combination of C-reactive protein and albumin), has been extensively validated since the original review.
Most of the prognostic tools (PPS, PaP and the PPI) depend largely on the assessment of functional status as a core component. Therefore, their use in routine practice has been sparse compared to Karnofsky Performance Score or the simplified Eastern Cooperative Oncology Group Performance Score. 24, 25 In addition the relatively complex scoring systems of these prognostic tools may have prejudiced their routine use; whilst the similarities but clear differences in these is confusing and makes comparison challenging. Therefore, it would be important to rationalise these subjective assessments into a simpler scheme with as advocated by From the present review it is also clear that many of the tools such as PaP, PPI, PPS and even performance status are predominantly subjective and it could be argued that where possible, these should be made more objective. For example, one such way would be to examine if skeletal muscle mass is related to functional status, and whether it can be a surrogate marker This excluded a large external validation study (n = 2,426) of the modified PiPS-A and -B prognostic tools reported by Baba and coworkers in May 2015. 30 Nevertheless present review is therefore a step towards the viewpoint of Harding and coworkers that 'it would be important to rationalise these subjective assessments into a simpler scheme with "judicious selection and refinement of existing tools' (The PRISMA Symposium 1: outcome tool use.
Disharmony in European outcomes research for palliative and advanced disease care: too many tools in practice). 31
Limitations
It is clear that with the exception of the GPS and contrary to the REMARK guidelines, HR and 95% CI have been reported inconsistently in the prognostic tools developed for use in patients with advanced cancer. This precluded meaningful meta-analysis in the present systematic review. Therefore, future research should directly compare these validated prognostic tools within all advanced cancer types using similar statistical approaches, in keeping with the REMARK guidelines. 32
The present systematic review updated a previous review published a decade ago. The majority of the prognostic tools examined had less than five independent reports of their prognostic value and therefore a meta-analysis of the validated prognostic tools was not meaningful and a formal estimate of bias was not carried out. However, the data from each paper was presented in detail (supplementary Table 1 ) enabling the reader to draw conclusions as to their quality and the likelihood of bias using standard criteria. As a result the present systematic review is largely descriptive giving an update in the progress of prognostic tools in the field.
Several key aspects of prognostic tools remain elusive and the present manuscript was unable to address these due to paucity of primary data. To illustrate, it is not clear if certain tools have greater utility in specific tumour types and/or at certain points in the cancer journey.
Further, the potential role of these clinical tools in clinical practice is unclear as their usefulness in treatment stratification or place of care planning is unknown; both of these are unlikely to be addressed unless such tools are incorporated into routine clinical practice.
It is also clear that another challenge is to implement the right tool at the right point in the patient's cancer journey. This is important as this can affect different aspects of care e.g.
whether to treat with anti-cancer therapy, preferred place of death etc. To date the application of the right tool, at the right time remains elusive and is likely to require a combination of mixed methodologies to achieve this.
Conclusion
Prognosis remains a central tenet of care in cancer, and validated tools applied correctly may serve to improve patient care. Since the previous systematic review and recommendations, many prognostic tools that have been examined are not integrated into routine clinical care. It could be argued that the multitude of tools available may have actually confused clinicians as to the optimal tool for use. Further, as performance status remains at the forefront of clinical decision making regarding prognosis, tools which build on this would seem preferable e.g.
the GPS and ECOG-PS. To provide some clarity as to the optimal prognostic tool, studies are needed which compare all independent prognostic markers, in a single population. Such studies are eagerly awaited. 1-12.5 12.6-19.5 M A N U S C R I P T A key component of the PaP is clinician predicted survival (CPS). It has been argued that CPS is dependent on physicians having sufficient knowledge and experience to make assess this adequately. From the eligible studies it was noted that oncologists' (i.e. non palliative care specialists) CPS was shown to be well calibrated but individual predictions imprecise.
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Using the CPS from non-specialists still enabled the PaP to predict the short term survival (30 days) of patients with advanced cancer 'reasonably well'. The inclusion of CPS, therefore, does not detract from the PaP score being a unique combination of physician's judgement, corrected and integrated with a series of other objective parameters, optimising the score. In spite of this, this tool is not used routinely. This may be due to its heavy reliance on CPS and therefore clinicians do not need to use a tool which weights their existing opinion heavily, and therefore they could argue will not alter their survival estimate. The other components of the tool have been individually validated for their accuracy in estimating prognosis, however the individual weighting of each parameter is not known since no study has compared every clinical and biomarker important in prognosis in advanced cancer.
BCI (B12/CRP Index) (Table6)
The BCI was developed by a group at the University of London, UK, following the EAPC's recommendations in 2005. It was initially validated in patients with advanced incurable cancer admitted to an elderly care facility. It can estimate up to 90 day mortality. Of interest M A N U S C R I P T
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is that the BCI incorporates vitamin B12 levels as a marker of prognosis; the rationale for this is that increased levels are present in myeloproliferative disorders, hepatocellular carcinoma and metastatic liver disease. It consists of two objective (biomarker) parameters, CRP and B12. However, vitamin B12 is not always analysed routinely in patients and may explain the lack of further research into this tool. Care Study) (Table 7) The PiPS was developed in a UK population with locally advanced or metastatic cancer. instead the tool is accessed electronically and a score issued.
PiPS (Prognosis in Palliative
PPI (Palliative Prognostic Index) (Table 8)
The PPI was developed in Japan in 1999, in patients with advanced incurable cancer. It divides survival into three groups and estimates survival up to 6 weeks. Risk group A (PPI score ≤4) has an estimated survival of more than six weeks. Risk group B (PPI score 5) has an estimated survival of less than six weeks but greater than three weeks. Risk group C (PPI score >6) has an estimated survival of less than three weeks. It consists of nine subjective parameters (the Palliative Performance Scale, oral intake, oedema, dyspnoea at rest and delirium) and reports the presence or absence of signs and symptoms with similar weighting given to the different parameters. One of the parameters used is the Palliative Performance Scale (PPS) that is a prognostic tool in its own right. By incorporating the PPS into the PPI, more subjective parameters are incorporated and whilst this may increase the prognostic accuracy, it may increases bias and the complexity and reduce clinical utility.
PPS (Palliative Performance Scale) (Table 9)
The PPS was validated in a palliative care population in Canada. It provides a percentage score based upon subjective indices giving a survival estimate up to 3 months. Survival M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT accuracy of intermediate scores has been noted to be variable. It consists of six subjective parameters. Many of these parameters are focussed on aspects of performance status including ambulation, activity levels and performance status itself. Performance status is the gold standard in assessing a patient's fitness, therefore this tool is bias towards performance status in that synonyms of performance status are included as parameters (e.g. levels of ambulation, activity and self-care). One of the other parameters is conscious level, which could have been objectified by incorporating the Glasgow Coma Scale.
In conclusion the PPS has been extensively studied in a large patient population with advanced cancer, including multiple cancer types. It has performed well in the majority of the studies looking at the tool individually, the only criticism being its better accuracy with lower PPS scores. It has also been compared several times with other prognostic tools with varying results and again demonstrates comparable accuracy to other tools with lower PPS scores.
The components of this tool are heavily bias towards performance status and disease burden emphasising the importance of these clinical markers in prognosis. Score) (Table 10) The GPS was originally developed in patients with non-small cell lung cancer and subsequently refined to the mGPS The GPS combines CRP and albumin to give a score of 0, 1 or 2, with increasing score suggesting decreased survival: CRP<10=0; CRP>10=1 (albumin >35); and CRP>10 + Albumin<35 =2 It has been validated in individual cancer types in addition to large populations of patients with advanced incurable cancer. 23 The GPS is entirely objective as the information needed to calculate the score is based on biomarker results. The GPS has been developed since the EAPC's recommendations in 2005 and meets the requirements set that any prognostic tool is quick and easy to use, and its scoring system is very simple. The GPS is also able to predict survival accurately several months prior to death. It fulfils the EAPC's recommendations of being quick and easy to use, along with robust evidence of its accuracy.
GPS (the Glasgow Prognostic
